Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Cefotiam
The First People's Hospital of Lianyungang
Gastric Varices
1 trial -
Celebrex
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Knee Osteoarthritis
1 trial -
Celecoxib
The First People's Hospital of Lianyungang
Low Back Pain
1 trial -
Celecoxib 400mg
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Peutz-Jeghers Syndrome
1 trial -
Chemotherapy drug
The First People's Hospital of Lianyungang
Hepatocellular Carcinoma, Adult
1 trial -
Chi-GVM
The First People's Hospital of Lianyungang
Relapsed/Refractory Peripheral T-cell Lymphoma
1 trial -
Chidamide
Xiyuan Hospital of China Academy of Chinese Medical Sciences
AML
1 trial -
Chidamide
Hospital Authority, Hong Kong
AML
1 trial -
Chinese herbal medicine
The First People's Hospital of Lianyungang
Acute on Chronic Liver Failure
1 trial -
Chinese herbs
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Depression
1 trial -
Ciprofol
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Sedation
1 trial -
Clarithromycin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Chronic Rhinosinusitis
1 trial -
Coenzyme Q10
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cardiovascular Disease
1 trial -
Coffee
Hospital Authority, Hong Kong
Insulin Resistance
1 trial -
Colchicine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Transcatheter Aortic Valve Replacement
1 trial -
Combination Product: Conventional third-line therapy
The First People's Hospital of Lianyungang
Colorectal Cancer (CRC)
1 trial -
Combination group
Hospital Authority, Hong Kong
Cardiac Arrest
1 trial -
Combination of chemotherapy and immunotherapy
The First People's Hospital of Lianyungang
Non Small Cell Lung Cancer
1 trial -
Combination of targeted biopsy and systematic biopsy
The First People's Hospital of Lianyungang
Prostate Cancer
1 trial -
Combination of targeted biopsy and systematic biopsy
Peking University Third Hospital
Prostate Cancer
1 trial -
Compound Norethisterone Enanthate Injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Contraception Behavior
1 trial -
Conservative treatment
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Pancreatitis
1 trial -
Contrast-enhanced ultrasound-guided core biopsy
The First People's Hospital of Lianyungang
Pancreatic Disease
1 trial -
Control lidocaine cream
The First People's Hospital of Lianyungang
Atopic Dermatitis
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources